Heat Biologics Announces First Patient Dosed in the First Phase 1 Trial of HS-130
First allogeneic, off-the-shelf cell therapy approach that enhances T-cell activation through localized OX40-mediated co-stimulation of dormant immune signals DURHAM, NC...